IP Library Granted Patent US 9,845,306
Granted Patent B2
US 9,845,306 · App. 14/828,751 · Granted Dec 19, 2017

Cationic lipid

Inventors: Takeshi Kuboyama (Tokyo, JP); Tomohiro Era (Tokyo, JP); Tomoyuki Naoi (Tokyo, JP)
Assignee: KYOWA HAKKO KIRIN CO., LTD.
C07D401/04A61K9/0019A61K9/1272A61K47/16A61K47/18A61K47/186A61K47/22C07C217/08C07C217/28C07C217/40C07C219/06C07C219/08C07C237/06C07C237/22C07C271/22C07D207/08C07D207/12C07D211/58C07D491/056C12N15/113C12N2310/14C12N2320/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,845,306
App. No.
14/828,751
Granted
Dec 19, 2017
Kind
B2
Abstract

The present invention provides a cationic lipid, which allow nucleic acids to be easily introduced into cells, represented by formula (I) (wherein: R 1 and R 2 are, the same or different, alkenyl, etc, and X 1 and X 3 are hydrogen atoms, or are combined together to form a single bond or alkylene, and X 3 is absent or is alkyl, etc, Y is absent or anion, a and b are, the same or different, 0 to 3, and L 3 is a single bond, etc, R 3 is alkyl, etc, L 1 and L 2 are —O—, —CO—O— or —O—CO—), a composition comprising the cationic lipid and a nucleic acid, and a method for introducing a nucleic acid into a cell by using the composition comprising the cationic lipid and the nucleic acid, and the like.

Claims (21)

1. A cationic lipid represented by formula (I):

wherein:

R 1 and R 2 are, the same or different, each linear or branched alkyl, alkenyl or alkynyl having: 12 to 24 carbon atoms, or R 1 and R 2 are combined together to form dialkylmethylene, dialkenylmethylene, dialkynylmethylene or alkylalkenylmethylene;

X 1 and X 2 are hydrogen atoms, or combined together to form a single bond or alkylene;

X 3 and Y are absent;

a and b are, the same or different, 1 to 3;

L 3 is a single bond;

R 3 is a hydrogen atom; and

L 1 and L 2 are, the same or different, —O— or

2. The cationic lipid according to claim 1 , wherein L 1 and L 2 are —O—, and R 1 and R 2 are dodecyl, tetradecyl, hexadecyl, octadecyl, icosyl, docosyl, tetracosyl, (Z)-tetradec-9-enyl, (Z)-hexadec-9-enyl, (Z)-octadec-6-enyl, (Z)-octadec-9-enyl, (E)-octadec-9-enyl, (Z)-octadec-11-enyl, (9Z,12Z)-octadec-9,12-dienyl, (9Z, 12Z, 15Z)-octadec-9, 12, 15-trienyl, (Z)-icos-11-enyl, (11Z,14Z)-icos-11,14-dienyl, 3,7, 11-trimethyldodeca-2,6,10-trienyl or 3,7, 11,15-tetramethylhexadec-2-enyl.

3. The cationic lipid according to claim 1 , wherein L 1 and L 2 are

and R 1 and R 2 are tridecyl, pentadecyl, heptadecyl, nonadecyl, heneicosyl, tricosyl, (Z)-tridec-8-enyl, (Z)-pentadec-8-enyl, (Z)-heptadec-5-envl, (Z)-heptadec-8-enyl, (E)-heptadec-8-enyl, (Z)-heptadec-10-enyl, (8Z,11Z)-heptadec-8,11-dienyl, (8Z, 11Z,14Z)-octadec-8, 11,14-trienyl, (Z)-nonadec-10-enyl, (10Z,13Z)-nonadec-10,13-dienyl, (11Z,14Z)-icos-11,14-dienyl, 2,6,10-trimethylundec-1,5,9-trienyl or 2,6,10,14-tetramethylpentadec-1-enyl.

4. The cationic lipid according to anyone of claims 1 to 3 , wherein a and b are both 1.

5. A composition that comprises the cationic lipid according to anyone of claims 1 to 3 , and a nucleic acid.

6. A composition comprising a complex particle of the cationic lipid according to any one of claims 1 to 3 and a nucleic acid, or a complex particle of a nucleic acid and a combination of the cationic lipid and a neutral lipid and/or a polymer.

7. A composition comprising a lipid particle constituted of a complex particle of the cationic lipid according to anyone of claims 1 to 3 and a nucleic acid, or a complex particle of a nucleic acid and a combination of the cationic lipid and a neutral lipid and/or a polymer, and a lipid membrane that encapsulates the complex particle.

8. The composition according to claim 6 , wherein the nucleic acid is a nucleic acid having an activity of suppressing the expression of the target gene by utilizing RNA interference (RNAi).

9. The composition according to claim 8 , wherein the target gene is a gene associated with tumor or inflammation.

10. A method for introducing the nucleic acid into a cell with the composition according to claim 6 wherein the method of the introduction into a cell is a method of introduction into a cell by intravenous administration.

11. The method according to claim 10 , wherein the cell is a cell at a tumor or inflammation site of a mammal.

12. The method according to claim 10 , wherein the cell is a cell in the liver, lungs, kidneys or spleen of a mammal.

Priority Claims (2)
JP 2010-104159 · Apr 28, 2010 · national
JP 2010-209937 · Sep 17, 2010 · national
Continuity (2)
Continuation 13643342
Related Publication 20150343062A1 · Dec 3, 2015